Leveraging Lessons Learned in Oncology to Support More Personalized Treatment of Neurodegenerative and Metabolic Diseases

Our team presented at Precision Medicine Outside of Oncology on understanding the current landscape of precision medicine and how best practices from the oncology pathway can support neurodegenerative and metabolic disease therapy development. Unique challenges and advances in biomarker discovery for transforming neurodegenerative research and development and exploring biomarkers as candidate diagnostics for complex, multifactorial chronic diseases including non-alcoholic fatty liver disease (fat accumulation in the liver not due to alcohol overconsumption, or NAFLD) and non-alcoholic steatohepatitis (NASH).